

ASX RELEASE

1 DECEMBER 2025



TETRATHERIX JOINT VENTURE BIOOPTIX SIGNS DEVELOPMENT AGREEMENT WITH ALCON

HIGHLIGHTS:

- **BioOptix, Inc.**, the ophthalmic biomaterials company jointly owned by **Tetratherix Limited**, has entered into an agreement with **Alcon Research, LLC**.
- BioOptix will continue to advance its portfolio of ophthalmic biomaterial solutions, including ongoing development of technologies derived from the **Tetramatrix™ platform**.
- Entering into a new strategic partnership, **Alcon Research, LLC** has agreed to provide funding via a corporate grant program subject to agreed development milestones that will accelerate the commercialisation of the products derived from the Tetramatrix™ platform technology.

BioOptix & Alcon Agreement

Tetratherix Limited (ASX:TTX) (Tetratherix), a developer of novel clinical products based on its patented biomaterial platform technology, announces that its joint venture partner **BioOptix, Inc.** (BioOptix) has executed an agreement with **Alcon Research, LLC** (Alcon).

BioOptix was established as a joint venture between Tetratherix and leading ophthalmic clinicians in the United States. BioOptix is an ophthalmic biomaterials company focused on launching a broad portfolio of innovative ophthalmic biomaterial technologies in the sector.

Under the terms of the agreement, Alcon has agreed to provide milestone-based development funding to complete a range of specific preclinical studies. The results from these preclinical studies will form an integral part of the medical device dossier for future regulatory submissions and market clearances.

Will Knox, CEO of Tetratherix:

"Securing a development funding agreement with a global tier-one leader like Alcon so early in the life of the BioOptix Joint Venture is a powerful validation of our Tetramatrix™ platform technology. It confirms that our synthetic, bio-resorbable materials are not just theoretically advantageous but commercially desirable to the biggest players in the medical device industry."

About BioOptix:

BioOptix is developing a portfolio of ophthalmic biomaterial technologies, including next-generation synthetic solutions derived from the Tetramatrix™ platform. These technologies are intended to address unmet needs in surgical workflows and ophthalmic care.

Authorised for release by CEO.

< ENDS >

For further information contact:

Jacob Pfeffer
+61 425 194 200
jacob.pfeffer@tetratherix.com
<https://tetratherix.com/>

For personal use only